• IGC Pharma secured a Canadian patent covering the composition of IGC-AD1, its investigational oral therapy for agitation in Alzheimer's disease.
• The grant extends protection within the same patent family across the U.S., Canada and Mexico.
• IGC-AD1 now has five granted patents, with 10 additional applications pending worldwide.
• The Phase 2 CALMA trial completed enrollment in September 2026 and is in its final dosing period.
• Topline results will follow database lock and unblinding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611051018ACCESSWRNAPR_____1247348) on November 05, 2026, and is solely responsible for the information contained therein.